Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceutical company aiming to become a global leader in the discovery, development and commercialisation of targeted therapies for oncology and immunological diseases. Hutchison MediPharma, has developed and progressed our broad pipeline of novel oral drug candidates for oncology and immunological diseases, which is in development in North America, Euro...
Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceutical company aiming to become a global leader in the discovery, development and commercialisation of targeted therapies for oncology and immunological diseases. Hutchison MediPharma, has developed and progressed our broad pipeline of novel oral drug candidates for oncology and immunological diseases, which is in development in North America, Europe, China and Australia. Chi-Med is listed on the London Stock Exchange’s AIM market and on the Nasdaq Global Select Market. It is majority owned by CK Hutchison Holdings Limited.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.